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Abstract Nuclear type 1 protein phosphatase (PPl) activity in primary culture of EGF-stimulated hepatocytes was significantly and transiently 
increased at the G,/S transition, being about 2.5-fold, while that in non-stimulated hepatocytes howed almost no change. On the other hand, 
non-nuclear PPl activity was gradually increased until the G,/S transition, but the activity showed no difference between EGF-stimulated and 
non-stimulated hepatocytes. Under growth-inhibited conditions in the presence of TGFpl, the increase in nuclear PPI activity was completely 
suppressed, whereas non-nuclear PPI activity was little affected. Such close correlation between nuclear PPl activity and growth factor-induced 
positive or negative growth signaling strongly suggests an involvement of PPI in progression from G, to S phase of hepatocytes. On Western 
immunoblotting using antisera for PPla, PPlyl, and PP16, no isoform showed any change in amount under these conditions. Mechanism(s) of 
growth-associated alterations in nuclear PPl activity is discussed. 
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1. Introduction 
There are several lines of evidence that epidermal growth 
factor (EGF) stimulates replicative DNA synthesis and that 
transforming growth factorB (TGFpl) strongly inhibits DNA 
synthesis in many mammalian cells including hepatocytes [ 1,2]. 
Recently it has become clear that phosphorylation of the reti- 
noblastoma gene product (RB) during G, is essential for pro- 
gression from G, into S phase [3]. In addition, it has been shown 
that TGFjIl causes the accumulation of unphosphorylated RB 
and the inhibition of Cdk2 and Cdk4 in late G,, resulting in G, 
arrest [4]. However, the regulatory mechanisms at the molecu- 
lar level by which the effects of EGF and TGFj?l are exerted 
still remain to be elucidated. 
Protein phosphatases, which functionally counteract protein 
kinases, play important roles in regulating the cell cycle. Type 
1 and type 2A protein phosphatases (PPl and PP2A) have been 
implicated in the control of the mitotic events in yeasts and 
mammalian cells [S]. However, it remains unclear yet whether 
PPl and/or PP2A is involved in the progression from G, into 
S in mammalian cells. We have reported that mRNA and pro- 
tein levels of PPla are increased in poorly differentiated ascites 
hepatomas [6,7,8,9], suggesting that PPla is closely linked to 
malignant potency and/or hepatocyte proliferation [lo]. We 
have also demonstrated that nuclear PPl activity is elevated at 
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12 h after partial hepatectomy, the time corresponding to the 
GJS transition of hepatocyte cell cycle [l 11. 
Therefore, we examine the effects of EGF and TGFjIl on 
PPl, in particular, those at the G,/S transition in primary cul- 
ture of hepatocytes. Here we show that TGFjIl inhibits an 
increase in nuclear PPl activity caused by EGF at the G,/S 
transition, while expression levels of three PPl isoforms, PPla, 
PPlyl, and PP16 [12], remain constant. 
2. Materials and methods 
2.1. Materials 
Leibovitz L-15 tissue culture medium (L-15), Dulbecco’s modified 
Eagle medium (DMEM) with high glucose and Ham’s F-12 (F-12) were 
obtained from Kyokuto Pharmaceutical Industries (Tokyo, Japan). 
ITX-premix (insulin, transferrin, and selenious acid) and EGF were 
purchased from Collaborative Reseach, Inc (Lexington, MA) and 
TGF/Il from human platelets was from R&D systems Inc. (Minneapo- 
lis, MN). Collagenase was from Yakult Honsha Co. Ltd. (Tokyo, 
Japan). Collagen was from Collagen Corp. (Palo Alto, CA). Percoll was 
obtained from Pharmacia (Uppsala, Sweden). 
2.2. Isolation of rat hepatocytes and cell culture 
Adult male Wistar rats (Japan SLC Inc.) weighing about 200 g were 
used to isolate hepatocytes by a collagenase perfusion technique [13] 
and viable hepatocytes were purified with Percoll [14]. The viability of 
purified hepatocytes was greater than 85% (assessed by Trypan blue dye 
exclusion). The cells were suspended in L-15 supplemented with 0.5 
mg/ml insulin, 1 mg/ml albumin, and lOO,@ml streptomycin, and then 
plated on collagen-coated ishes at a cell density of 2 x 10’ ceils/35-mm 
dish or 2 x lo6 cells/lOO-mm dish. Two hours after start of culture 
(plating), the medium was changed to a mixture of F-12 and DMEM 
(1: 1) supplemented with 5 &ml insulin, 5 &ml transferrin, 5 ng/ml 
selenious acid, lo-’ M dexamethasone, the antibiotics, and 20 rig/ml 
EGF. The medium was renewed at 24 h after plating. 
2.3. Measurement of DNA synthesis 
DNA synthesis was determined by measurement of [‘Hlthymidine 
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incorporation into DNA. Cells (5 x 104) were cultured in the absence 
or presence of EGF (20 @ml) and various concentrations of TGF/Il 
in a 12-well plate (22-mm diameter). The cultures were treated with 
1 PCi of [‘Hlthymidine for 4 h prior to harvest. Then the incorporation 
into DNA was measured as described previously [15]. 
2.4. Subcellular fractionation 
Nuclei were isolated essentially by the method of Blobel and Potter 
[16] with a slight modification as described by Kuret et al. [17]. Cells 
(1 x 10’) growing on five loo-mm dishes were harvested at the indicated 
times by trypsinizing and scraping. Cells were then pelleted at 2,000 x g, 
suspended in 300 ~1 of buffer A (10 mM Tris-HCl, pH 7.5,lO mM KCl, 
2 mM MgCl,, 1 mM DTT, 1 mM benzamidine, 10 &ml leupeptin, 
10 &ml pepstatin, and 1 mM PMSF) containing 0.25 M sucrose and 
0.1% NP-40. and homogenized bv 5 x 5 strokes on ice in a glass-Teflon 
homogenizer. The resulting homogenate was mixed with 600 ~1 of 
buffer A containing 2.3 M sucrose. Subsequently the mixture was un- 
derlaid by 300~1 of buffer A containing 2.3 M sucrose and centrifuged 
at 124,000 x g for 30 min. The resulting supernatant was termed non- 
nuclear fraction. The nuclear pellets were resuspended in 300 ml of 
buffer A containing 0.25 M sucrose and 0.1% NP-40, syringed through 
a 25-gauge needle five times to remove the outer nuclear membrane, 
and pelleted by centrifugation for 5 min at 800 x g. The white nuclear 
pellets were resuspended in 75 ~1 of buffer B (50 mM Tris-HCl, pH 7.5, 
25 mM KCl, 5 mM MgCl,, 0.1% 2ME, 0.1 mM PMSF, 1 mM ben- 
zamidine, and 10 mM EDTA), and then the nuclei were lysed by adding 
25 ~1 of buffer C (50 mM Tris-HCl, pH 7.5,0.1% 2ME, and 2 M NaCl). 
The resulting suspension was termed nuclear fraction. To examine the 
purity of isolated nuclear fraction, the activity of glucosed-phosphat- 
ase, microsome marker enzyme, was determined. The activity per 
2 x lo6 cells and specific activity in microsome were 0.182 unit and 0.21 
unit/mg protein, respectively. In contrast, those in nuclear fraction were 
0.0012 unit and 0.013 unit/mg protein, respectively. One unit of activity 
was defined as the amount of enzyme that catalyzes the release of 
1 pmol of phosphate per min. Thus, the contamination of microsome 
into the nuclear fraction was negligible. 
2.5. Phosphatase assay 
PPl activity was measured by the method of Cohen, P. et al. [18] with 
a slight modification as described in detail previously [19]. “P-Labeled 
rabbit skeletal muscle phosphorylase a (lo6 cprn/nmol) was used as a 
substrate. PPl was defined as the phosphorylase phosphatase activity 
that is sensitive to inhibitor-2. Nuclear PPl activity was defined as the 
activity of the lysed nuclear fraction minus that of the resuspended 
nuclear pellets just before lysis. One unit of activity (U) was defined as 
the amount of enzyme that catalyzes the release of 1 pmol of phosphate 
per min. 
2.6. Western immunoblotting 
Subcellular fractions of hepatocytes were electrophoresed on a 12% 
polyacrylamide gel by Laemmli’s procedure [20] and proteins were 
electrophoretically transferred to a nitrocellulose filter. The filter was 
incubated with blocking solution and then with rabbit antibodies 
against synthetic peptides identical to the carboxyl-termini of PPla, 
PPlyl, and PP16 for 1 h at room temperature as described previously 
[8]. After washes in PBS containing 0.1% Tween 20, the filter was 
incubated with horseradish peroxidase-conjugated donkey anti-rabbit 
IgG for 1 h. Detection of the immune signal was done by using ECL 
Western blotting detection system (Amersham). 
2.7. Protein determination 
Protein concentrations were measured by the procedure of Bradford 
[21], using bovine serum albumin as the standard. 
3. Results 
3.1. DNA synthesis of cultured hepatocytes 
As shown in Fig. lA, hepatocytes treated with EGF started 
DNA synthesis 3640 h after plating, reached a peak at 44 h, 
when about 80% of the cells incorporated [3H]thymidine into 
DNA (data not shown). These data indicate that the time 3640 
h corresponds to the G,/S transition in EGF-stimulated hepato- 
cytes. Next, TGFjIl was added at different times (2,24,36, and 
40 h) and various concentrations (0.5, 1.5, and 3 @ml), then 
DNA synthesis at 44 h was measured. As shown in Fig. lB, 
TGFBl added at 2 h and 24 h caused about 95% reduction of 
DNA synthesis. However, TGF/Il added at 36 h inhibited only 
3040% and that added at 40 h showed no effect. 
3.2. PPl activity in subcellular fractions of EGF-stimulated 
hepatocytes 
In non-nuclear fractions (Fig. 2A), PPl activity either with 
or without EGF treatment was gradually increased until 40 h 
and then decreased. There was no difference between the activ- 
ities with and without EGF. In nuclear fractions (Fig. 2B), PPl 
activity with or without EGF treatment showed almost no 
change until 36 h. Thereafter the activity with EGF treatment 
was significantly and transiently increased at 40 h, being about 
2.5fold over the activities at 12 h and 24 h and the correspond- 
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Fig. 1. DNA synthesis of cultured hepatocytes treated with EGF and 
EGF plus TGFBl. (A) [‘HlThyrnidine incorporation of hepatocytes in 
the presence @) or absence (0) of EGF was measured at the indicated 
times after plating. (B) 0.5 (open bars), 1.5 (hatched bars), and 3.0 ng/ml 
(solid bars) of TGFBl were added to the culture containing EGF at the 
indicated times. Cells (5 x 104) were harvested at 44 h and then [‘HIthy- 
midine incorporated was measured. Control denotes [‘Hlthymidine in- 
corporation at 44 h in EGF-stimulated hepatocytes. Error bars indicate 
one standard deviation in four separate xperiments. 
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treatment showed only slight increase. Then both activities 
maintained almost similar levels to those at 36 h. 
3.3. Effect of TGFBI on PPI activity 
TGFpl showed almost no effect on non-nuclear PPl activity 
at 40 h (Fig. 3A). In contrast, TGFpl suppressed the increase 
in nuclear PPl activity caused by EGF at 40 h in proportion 
to its growth-inhibitory effect (Figs. 1B and 3B). Namely, when 
TGF/31 was added at 2 h or 24 h, it completely inhibited DNA 
synthesis and at the same time suppressed the nuclear PPl 
activity to the level of non-stimulated hepatocytes; when 
TGF/31 was added at 36 h, it inhibited DNA synthesis by only 
3040% and also suppressed 30-40% of the increase in nuclear 
PPl activity caused by EGF. 
3.4. Western immunoblotting 
To investigate whether the changes in nuclear PPl activity 
in EGF-stimulated hepatocytes i  through an accumulation of 
PPl protein, we performed Western immunoblotting of nuclear 
fractions at 36 h, 40 h, and 44 h using rabbit antisera for PPla, 
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Fig. 2. PPI activity in EGF-stimulated hepatocytes. PPl activities in 
non-nuclear (A) and nuclear (B) fractions of hepatocytes cultured for 
the indicated times in the presence (0) or absence (0) of EGF were 
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Fig. 3. Effect of TGFBl on PPl activity. TGFBl was added at a 
concentration of 1.5 ng/ml and at the times(h) indicated in parentheses. 
Cells (1 x 10’) were harvested at 40 h and their non-nuclear (A) and 
nuclear (B) fractions were assayed for PPl activity. The activities at 
40 h in EGF-stimulated and non-stimulated hepatocytes are also pre- 
sented. Results were compiled from four separate experiments. 
antisera used was confirmed by peptide-competition test. The 
amounts of three isoforms together emained almost constant 
from 36 h to 44 h in EGF-stimulated hepatocytes (Fig. 4B and 
C). Moreover, TGF/31 showed no effect on the amount of any 
nuclear PPl isoform at 40 h after plating (Fig. 5). Although we 
examined mRNA and protein levels of PPl isoforms in more 
expanded time course (6 h to 48 h after plating) in EGF- 
stimulated hepatocytes, neither mRNA nor protein level of any 
PPl isoform showed obvious change (data not shown). 
4. Discussion 
In the present study, first we have demonstrated that nuclear 
PPl activity is significantly and transiently increased at the G,/S 
transition in EGF-stimulated hepatocytes, but not in non-stim- 
ulated hepatocytes. This finding is in accord with our previous 
results of in vivo regenerating livers [ll]. Second, to further 
explore a relationship between nuclear PPl and cell growth at 
the G,-S phase, we examined the nuclear PPl activity in the 
presence of TGFBl, a negative growth factor whose final target 
molecule(s) is believed to be in late G, [4]. We have shown that 
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Fig. 4. Specificity of the antisera and protein expressions of nuclear PPl isoforms. (A), peptide-competition test was performed. Each antiserum was 
preincubdted with the corresponding peptide (final 10 PM) and then the blots of nuclear fraction of hepatocytes were incubated with the neutralized 
antisera. (B), Western immunoblotting analysis using the peptide antisera for PPla, PPlyl, and PP16 was performed for nuclear fractions of 36-h, 
40-h. and 44-h cultured cells. The fractions containing 3 pg of protein were subjected to SDS-PAGE on a 12% polyacrylamide gel and transferred 
to a nitrocellulose filter. Representative result was shown among three separate xperiments. (C), the relative amounts of PPlol (o), PPlyl (o), and 
PP16 (n) were quantified by densitometric scanning. Results are expressed as a ratio for the amount at 36 h. 
TGF/31 suppresses the increase in nuclear PPl activity at the So far, there are several reports that catalytic subunit of PPl 
G,/S transition of EGF-stimulated hepatocytes, in a growth is phosphorylated in vitro by v-abl tyrosine kinase [24], cdc2 
inhibition-dependent manner. Therefore it seems that nuclear kinase [25], and pp60”+” [26], resulting in modulation of PPl 
PPl activity is subjected to stimulatory or inhibitory regulation activity. Regarding regulatory subunit of nuclear PPl, the exis- 
by EGF or TGFbl, respectively, and thus nuclear PPl is in- tence of nuclear inhibitor protein of PPl, termed NIPP-1, has 
volved in progression from G, into S phase of hepatocytes. been reported [27] in addition to inhibitor-2 [28]. 
Recently Gruppuso et al. have reported that growth arrest Recently, we have demonstrated that mRNA and protein 
in human keratinocytes by TGFBl involves activation of PPl levels of PPla were specifically increased in poorly differen- 
[22], which is incompatible with our results. The intracellular ciated ascites hepatomas compared with normal liver [7,8,9]. In 
events in response to EGF plus TGF/31 might be different contrast, in growth-stimulated hepatocytes induced by EGF, 
between hepatocytes and keratinocytes. In fact, they have both mRNA and protein levels of PPla remained constant 
shown in keratinocytes that protein content per cell is increased during the culture. The significance of this difference remains 
after exposure to TGFpl. However, in our experiments with unknown. Further study to elucidate the significance of the 
hepatocytes, protein content showed no change after plating different expression of PPl isoforms between hepatocytes and 
(data not shown), which is consistent with the report previously hepatomas will provide a clue to understanding of malignant 
published [23]. growth as well as normal proliferation of hepatocytes. 
On Western immunoblotting performed in order to investi- 
gate the mechanism of the changes in nuclear PPl activity, the 
amounts of three PPl isoforms, PPla, PPlyl, or PP16, did not 
change in either EGF-treated or EGF plus TGFpl-treated 
hepatocytes. Therefore, the mechanisms by which EGF en- 
hances nuclear PPl activity and TGFBl suppresses the increase 
may be attributed to post-translational processes such as: 
(1) modification of catalytic subunit of PPl itself, for example, 
phosphorylation-dephosphorylation; (2) binding or release of 
regulatory subunit(s). 
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Fig. 5. Effect of TGF/?l on protein expression of PPl isoforms in the 
nucleus. TGFBl (1.5 &ml) was added to the medium containing EGF 
at 24 h after plating. Cells were harvested at 40 h and then their nuclear 
fractions (3 pg protein/lane) were subjected to Western immunoblotting 
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